Pharma majors AbbVie and Roche were both trading lower early Tuesday after top-line results were announced from the global ...

Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...